Australia's most trusted
source of pharma news
Sunday, 22 December 2024
Posted 22 July 2022 PM
A GSK veteran of 20-plus years who rose to become global R&D Head of the company's vaccine unit is going head-to-head with his former employer via a spin-off from the University of Queensland (UQ).
Emmanuel Hannon has joined Vicebio as CEO, a London start up founded by investment firm Medicxi in 2019, to develop novel respiratory vaccines using the molecular clamp platform developed by UQ.
Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.
Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.